nodes	percent_of_prediction	percent_of_DWPC	metapath
Methysergide—HTR2B—Sorafenib—thyroid cancer	0.397	0.606	CbGbCtD
Methysergide—HTR2C—Sorafenib—thyroid cancer	0.258	0.394	CbGbCtD
Methysergide—Gastrointestinal symptom NOS—Sorafenib—thyroid cancer	0.00914	0.0363	CcSEcCtD
Methysergide—Gravitational oedema—Epirubicin—thyroid cancer	0.00814	0.0323	CcSEcCtD
Methysergide—Gravitational oedema—Doxorubicin—thyroid cancer	0.00753	0.0299	CcSEcCtD
Methysergide—Leg edema—Epirubicin—thyroid cancer	0.00738	0.0292	CcSEcCtD
Methysergide—Pleural effusion—Sorafenib—thyroid cancer	0.00702	0.0278	CcSEcCtD
Methysergide—Leg edema—Doxorubicin—thyroid cancer	0.00682	0.0271	CcSEcCtD
Methysergide—Neutropenia—Vandetanib—thyroid cancer	0.00467	0.0185	CcSEcCtD
Methysergide—Dysuria—Vandetanib—thyroid cancer	0.00467	0.0185	CcSEcCtD
Methysergide—Weight decreased—Vandetanib—thyroid cancer	0.00452	0.0179	CcSEcCtD
Methysergide—Pain in extremity—Sorafenib—thyroid cancer	0.0039	0.0155	CcSEcCtD
Methysergide—Alopecia—Vandetanib—thyroid cancer	0.00354	0.014	CcSEcCtD
Methysergide—Neutropenia—Sorafenib—thyroid cancer	0.00315	0.0125	CcSEcCtD
Methysergide—Weight decreased—Sorafenib—thyroid cancer	0.00305	0.0121	CcSEcCtD
Methysergide—Convulsion—Vandetanib—thyroid cancer	0.00302	0.012	CcSEcCtD
Methysergide—Arthralgia—Vandetanib—thyroid cancer	0.00297	0.0118	CcSEcCtD
Methysergide—Chest pain—Vandetanib—thyroid cancer	0.00297	0.0118	CcSEcCtD
Methysergide—Oedema—Vandetanib—thyroid cancer	0.00284	0.0113	CcSEcCtD
Methysergide—Thrombocytopenia—Vandetanib—thyroid cancer	0.00278	0.011	CcSEcCtD
Methysergide—Pleural effusion—Epirubicin—thyroid cancer	0.00259	0.0103	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00259	0.0103	CcSEcCtD
Methysergide—Insomnia—Vandetanib—thyroid cancer	0.00257	0.0102	CcSEcCtD
Methysergide—Paraesthesia—Vandetanib—thyroid cancer	0.00255	0.0101	CcSEcCtD
Methysergide—Dyspnoea—Vandetanib—thyroid cancer	0.00253	0.0101	CcSEcCtD
Methysergide—Hyperaesthesia—Epirubicin—thyroid cancer	0.00253	0.01	CcSEcCtD
Methysergide—Flushing—Sorafenib—thyroid cancer	0.00251	0.00993	CcSEcCtD
Methysergide—Dyspepsia—Vandetanib—thyroid cancer	0.0025	0.00992	CcSEcCtD
Methysergide—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00245	0.00973	CcSEcCtD
Methysergide—Fatigue—Vandetanib—thyroid cancer	0.00245	0.00972	CcSEcCtD
Methysergide—Constipation—Vandetanib—thyroid cancer	0.00243	0.00964	CcSEcCtD
Methysergide—Pain—Vandetanib—thyroid cancer	0.00243	0.00964	CcSEcCtD
Methysergide—Pleural effusion—Doxorubicin—thyroid cancer	0.0024	0.00952	CcSEcCtD
Methysergide—Alopecia—Sorafenib—thyroid cancer	0.00239	0.00946	CcSEcCtD
Methysergide—Hyperaesthesia—Doxorubicin—thyroid cancer	0.00234	0.00929	CcSEcCtD
Methysergide—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00232	0.00922	CcSEcCtD
Methysergide—Abdominal pain—Vandetanib—thyroid cancer	0.00225	0.00891	CcSEcCtD
Methysergide—Body temperature increased—Vandetanib—thyroid cancer	0.00225	0.00891	CcSEcCtD
Methysergide—Oliguria—Epirubicin—thyroid cancer	0.00216	0.00855	CcSEcCtD
Methysergide—Asthenia—Vandetanib—thyroid cancer	0.00204	0.00809	CcSEcCtD
Methysergide—Arthralgia—Sorafenib—thyroid cancer	0.002	0.00793	CcSEcCtD
Methysergide—Myalgia—Sorafenib—thyroid cancer	0.002	0.00793	CcSEcCtD
Methysergide—Oliguria—Doxorubicin—thyroid cancer	0.00199	0.00791	CcSEcCtD
Methysergide—Diarrhoea—Vandetanib—thyroid cancer	0.00195	0.00771	CcSEcCtD
Methysergide—Dizziness—Vandetanib—thyroid cancer	0.00188	0.00745	CcSEcCtD
Methysergide—Thrombocytopenia—Sorafenib—thyroid cancer	0.00188	0.00745	CcSEcCtD
Methysergide—Blood urea increased—Epirubicin—thyroid cancer	0.00188	0.00744	CcSEcCtD
Methysergide—Vomiting—Vandetanib—thyroid cancer	0.00181	0.00717	CcSEcCtD
Methysergide—Rash—Vandetanib—thyroid cancer	0.00179	0.00711	CcSEcCtD
Methysergide—Dermatitis—Vandetanib—thyroid cancer	0.00179	0.0071	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00175	0.00693	CcSEcCtD
Methysergide—Blood urea increased—Doxorubicin—thyroid cancer	0.00174	0.00688	CcSEcCtD
Methysergide—Dyspnoea—Sorafenib—thyroid cancer	0.00171	0.00678	CcSEcCtD
Methysergide—Nausea—Vandetanib—thyroid cancer	0.00169	0.0067	CcSEcCtD
Methysergide—Dyspepsia—Sorafenib—thyroid cancer	0.00169	0.00669	CcSEcCtD
Methysergide—Thrombophlebitis—Epirubicin—thyroid cancer	0.00167	0.00661	CcSEcCtD
Methysergide—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00166	0.00657	CcSEcCtD
Methysergide—Fatigue—Sorafenib—thyroid cancer	0.00165	0.00656	CcSEcCtD
Methysergide—Constipation—Sorafenib—thyroid cancer	0.00164	0.0065	CcSEcCtD
Methysergide—Pain—Sorafenib—thyroid cancer	0.00164	0.0065	CcSEcCtD
Methysergide—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00157	0.00622	CcSEcCtD
Methysergide—Thrombophlebitis—Doxorubicin—thyroid cancer	0.00154	0.00611	CcSEcCtD
Methysergide—Abdominal pain—Sorafenib—thyroid cancer	0.00152	0.00601	CcSEcCtD
Methysergide—Body temperature increased—Sorafenib—thyroid cancer	0.00152	0.00601	CcSEcCtD
Methysergide—Pain in extremity—Epirubicin—thyroid cancer	0.00144	0.00572	CcSEcCtD
Methysergide—Asthenia—Sorafenib—thyroid cancer	0.00138	0.00546	CcSEcCtD
Methysergide—Ataxia—Epirubicin—thyroid cancer	0.00136	0.00538	CcSEcCtD
Methysergide—Pain in extremity—Doxorubicin—thyroid cancer	0.00133	0.00529	CcSEcCtD
Methysergide—Orthostatic hypotension—Epirubicin—thyroid cancer	0.00132	0.00522	CcSEcCtD
Methysergide—Diarrhoea—Sorafenib—thyroid cancer	0.00131	0.0052	CcSEcCtD
Methysergide—Dizziness—Sorafenib—thyroid cancer	0.00127	0.00503	CcSEcCtD
Methysergide—Ataxia—Doxorubicin—thyroid cancer	0.00125	0.00498	CcSEcCtD
Methysergide—Eosinophilia—Epirubicin—thyroid cancer	0.00123	0.00489	CcSEcCtD
Methysergide—Vomiting—Sorafenib—thyroid cancer	0.00122	0.00484	CcSEcCtD
Methysergide—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.00122	0.00483	CcSEcCtD
Methysergide—Rash—Sorafenib—thyroid cancer	0.00121	0.00479	CcSEcCtD
Methysergide—Dermatitis—Sorafenib—thyroid cancer	0.00121	0.00479	CcSEcCtD
Methysergide—HTR1F—head—thyroid cancer	0.00117	0.106	CbGeAlD
Methysergide—Neutropenia—Epirubicin—thyroid cancer	0.00117	0.00462	CcSEcCtD
Methysergide—Dysuria—Epirubicin—thyroid cancer	0.00117	0.00462	CcSEcCtD
Methysergide—Eosinophilia—Doxorubicin—thyroid cancer	0.00114	0.00453	CcSEcCtD
Methysergide—Nausea—Sorafenib—thyroid cancer	0.00114	0.00452	CcSEcCtD
Methysergide—Weight increased—Epirubicin—thyroid cancer	0.00113	0.0045	CcSEcCtD
Methysergide—Weight decreased—Epirubicin—thyroid cancer	0.00113	0.00447	CcSEcCtD
Methysergide—Drowsiness—Epirubicin—thyroid cancer	0.00111	0.00441	CcSEcCtD
Methysergide—Neutropenia—Doxorubicin—thyroid cancer	0.00108	0.00428	CcSEcCtD
Methysergide—Dysuria—Doxorubicin—thyroid cancer	0.00108	0.00428	CcSEcCtD
Methysergide—Weight increased—Doxorubicin—thyroid cancer	0.00105	0.00416	CcSEcCtD
Methysergide—Weight decreased—Doxorubicin—thyroid cancer	0.00104	0.00414	CcSEcCtD
Methysergide—Drowsiness—Doxorubicin—thyroid cancer	0.00103	0.00408	CcSEcCtD
Methysergide—HTR1E—head—thyroid cancer	0.00101	0.0916	CbGeAlD
Methysergide—Oedema peripheral—Epirubicin—thyroid cancer	0.000983	0.0039	CcSEcCtD
Methysergide—Flushing—Epirubicin—thyroid cancer	0.000926	0.00367	CcSEcCtD
Methysergide—Oedema peripheral—Doxorubicin—thyroid cancer	0.000909	0.00361	CcSEcCtD
Methysergide—Alopecia—Epirubicin—thyroid cancer	0.000881	0.0035	CcSEcCtD
Methysergide—HTR7—neck—thyroid cancer	0.000876	0.0791	CbGeAlD
Methysergide—Flushing—Doxorubicin—thyroid cancer	0.000857	0.0034	CcSEcCtD
Methysergide—Back pain—Epirubicin—thyroid cancer	0.00084	0.00333	CcSEcCtD
Methysergide—Alopecia—Doxorubicin—thyroid cancer	0.000816	0.00323	CcSEcCtD
Methysergide—Ill-defined disorder—Epirubicin—thyroid cancer	0.000806	0.0032	CcSEcCtD
Methysergide—SIGMAR1—saliva-secreting gland—thyroid cancer	0.0008	0.0722	CbGeAlD
Methysergide—HTR6—head—thyroid cancer	0.000796	0.0718	CbGeAlD
Methysergide—Malaise—Epirubicin—thyroid cancer	0.000783	0.00311	CcSEcCtD
Methysergide—Back pain—Doxorubicin—thyroid cancer	0.000777	0.00308	CcSEcCtD
Methysergide—Convulsion—Epirubicin—thyroid cancer	0.000752	0.00298	CcSEcCtD
Methysergide—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000745	0.00296	CcSEcCtD
Methysergide—Myalgia—Epirubicin—thyroid cancer	0.000739	0.00293	CcSEcCtD
Methysergide—Chest pain—Epirubicin—thyroid cancer	0.000739	0.00293	CcSEcCtD
Methysergide—Arthralgia—Epirubicin—thyroid cancer	0.000739	0.00293	CcSEcCtD
Methysergide—Discomfort—Epirubicin—thyroid cancer	0.00073	0.0029	CcSEcCtD
Methysergide—Malaise—Doxorubicin—thyroid cancer	0.000725	0.00287	CcSEcCtD
Methysergide—Oedema—Epirubicin—thyroid cancer	0.000709	0.00281	CcSEcCtD
Methysergide—Convulsion—Doxorubicin—thyroid cancer	0.000696	0.00276	CcSEcCtD
Methysergide—Thrombocytopenia—Epirubicin—thyroid cancer	0.000694	0.00275	CcSEcCtD
Methysergide—Tachycardia—Epirubicin—thyroid cancer	0.000692	0.00274	CcSEcCtD
Methysergide—Arthralgia—Doxorubicin—thyroid cancer	0.000684	0.00271	CcSEcCtD
Methysergide—Myalgia—Doxorubicin—thyroid cancer	0.000684	0.00271	CcSEcCtD
Methysergide—Chest pain—Doxorubicin—thyroid cancer	0.000684	0.00271	CcSEcCtD
Methysergide—Discomfort—Doxorubicin—thyroid cancer	0.000676	0.00268	CcSEcCtD
Methysergide—Oedema—Doxorubicin—thyroid cancer	0.000656	0.0026	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000646	0.00256	CcSEcCtD
Methysergide—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000642	0.00255	CcSEcCtD
Methysergide—Insomnia—Epirubicin—thyroid cancer	0.000641	0.00254	CcSEcCtD
Methysergide—Tachycardia—Doxorubicin—thyroid cancer	0.00064	0.00254	CcSEcCtD
Methysergide—Paraesthesia—Epirubicin—thyroid cancer	0.000636	0.00252	CcSEcCtD
Methysergide—Dyspnoea—Epirubicin—thyroid cancer	0.000632	0.00251	CcSEcCtD
Methysergide—Somnolence—Epirubicin—thyroid cancer	0.00063	0.0025	CcSEcCtD
Methysergide—Dyspepsia—Epirubicin—thyroid cancer	0.000624	0.00247	CcSEcCtD
Methysergide—SIGMAR1—trachea—thyroid cancer	0.000617	0.0557	CbGeAlD
Methysergide—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000612	0.00243	CcSEcCtD
Methysergide—Fatigue—Epirubicin—thyroid cancer	0.000611	0.00242	CcSEcCtD
Methysergide—Constipation—Epirubicin—thyroid cancer	0.000606	0.0024	CcSEcCtD
Methysergide—Pain—Epirubicin—thyroid cancer	0.000606	0.0024	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000597	0.00237	CcSEcCtD
Methysergide—Insomnia—Doxorubicin—thyroid cancer	0.000593	0.00235	CcSEcCtD
Methysergide—Paraesthesia—Doxorubicin—thyroid cancer	0.000589	0.00234	CcSEcCtD
Methysergide—Dyspnoea—Doxorubicin—thyroid cancer	0.000585	0.00232	CcSEcCtD
Methysergide—Feeling abnormal—Epirubicin—thyroid cancer	0.000584	0.00232	CcSEcCtD
Methysergide—Somnolence—Doxorubicin—thyroid cancer	0.000583	0.00231	CcSEcCtD
Methysergide—Gastrointestinal pain—Epirubicin—thyroid cancer	0.00058	0.0023	CcSEcCtD
Methysergide—Dyspepsia—Doxorubicin—thyroid cancer	0.000577	0.00229	CcSEcCtD
Methysergide—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000566	0.00225	CcSEcCtD
Methysergide—Fatigue—Doxorubicin—thyroid cancer	0.000565	0.00224	CcSEcCtD
Methysergide—Constipation—Doxorubicin—thyroid cancer	0.000561	0.00222	CcSEcCtD
Methysergide—Pain—Doxorubicin—thyroid cancer	0.000561	0.00222	CcSEcCtD
Methysergide—Body temperature increased—Epirubicin—thyroid cancer	0.00056	0.00222	CcSEcCtD
Methysergide—Abdominal pain—Epirubicin—thyroid cancer	0.00056	0.00222	CcSEcCtD
Methysergide—HTR2A—neck—thyroid cancer	0.000546	0.0493	CbGeAlD
Methysergide—Feeling abnormal—Doxorubicin—thyroid cancer	0.00054	0.00214	CcSEcCtD
Methysergide—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000536	0.00213	CcSEcCtD
Methysergide—HTR7—trachea—thyroid cancer	0.000527	0.0476	CbGeAlD
Methysergide—Body temperature increased—Doxorubicin—thyroid cancer	0.000518	0.00206	CcSEcCtD
Methysergide—Abdominal pain—Doxorubicin—thyroid cancer	0.000518	0.00206	CcSEcCtD
Methysergide—Asthenia—Epirubicin—thyroid cancer	0.000508	0.00202	CcSEcCtD
Methysergide—SIGMAR1—thyroid gland—thyroid cancer	0.000488	0.0441	CbGeAlD
Methysergide—HTR2B—thyroid gland—thyroid cancer	0.000487	0.044	CbGeAlD
Methysergide—Diarrhoea—Epirubicin—thyroid cancer	0.000485	0.00192	CcSEcCtD
Methysergide—HTR1B—head—thyroid cancer	0.00048	0.0433	CbGeAlD
Methysergide—Asthenia—Doxorubicin—thyroid cancer	0.00047	0.00187	CcSEcCtD
Methysergide—Dizziness—Epirubicin—thyroid cancer	0.000469	0.00186	CcSEcCtD
Methysergide—HTR1D—head—thyroid cancer	0.000464	0.0419	CbGeAlD
Methysergide—HTR2C—head—thyroid cancer	0.00046	0.0415	CbGeAlD
Methysergide—Vomiting—Epirubicin—thyroid cancer	0.000451	0.00179	CcSEcCtD
Methysergide—Diarrhoea—Doxorubicin—thyroid cancer	0.000449	0.00178	CcSEcCtD
Methysergide—Rash—Epirubicin—thyroid cancer	0.000447	0.00177	CcSEcCtD
Methysergide—Dermatitis—Epirubicin—thyroid cancer	0.000446	0.00177	CcSEcCtD
Methysergide—Dizziness—Doxorubicin—thyroid cancer	0.000434	0.00172	CcSEcCtD
Methysergide—HTR2B—head—thyroid cancer	0.000432	0.039	CbGeAlD
Methysergide—Nausea—Epirubicin—thyroid cancer	0.000421	0.00167	CcSEcCtD
Methysergide—Vomiting—Doxorubicin—thyroid cancer	0.000417	0.00165	CcSEcCtD
Methysergide—Rash—Doxorubicin—thyroid cancer	0.000413	0.00164	CcSEcCtD
Methysergide—Dermatitis—Doxorubicin—thyroid cancer	0.000413	0.00164	CcSEcCtD
Methysergide—Nausea—Doxorubicin—thyroid cancer	0.00039	0.00154	CcSEcCtD
Methysergide—HTR1A—head—thyroid cancer	0.000387	0.0349	CbGeAlD
Methysergide—HTR7—head—thyroid cancer	0.00037	0.0334	CbGeAlD
Methysergide—HTR2A—trachea—thyroid cancer	0.000329	0.0297	CbGeAlD
Methysergide—SIGMAR1—lymph node—thyroid cancer	0.000303	0.0274	CbGeAlD
Methysergide—HTR2B—lymph node—thyroid cancer	0.000303	0.0273	CbGeAlD
Methysergide—HTR2A—head—thyroid cancer	0.000231	0.0208	CbGeAlD
Methysergide—HTR1E—Signaling Pathways—CALCA—thyroid cancer	9.91e-05	0.00121	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—TSHR—thyroid cancer	9.79e-05	0.00119	CbGpPWpGaD
Methysergide—HTR1A—GPCR downstream signaling—SST—thyroid cancer	9.7e-05	0.00118	CbGpPWpGaD
Methysergide—HTR2C—GPCR downstream signaling—SST—thyroid cancer	9.65e-05	0.00118	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—PTCH1—thyroid cancer	9.63e-05	0.00118	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—PRKAR1A—thyroid cancer	9.63e-05	0.00118	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—PTCH1—thyroid cancer	9.58e-05	0.00117	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—CDK1—thyroid cancer	9.51e-05	0.00116	CbGpPWpGaD
Methysergide—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	9.47e-05	0.00116	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—CDK1—thyroid cancer	9.47e-05	0.00116	CbGpPWpGaD
Methysergide—HTR1A—GPCR downstream signaling—CALCA—thyroid cancer	9.34e-05	0.00114	CbGpPWpGaD
Methysergide—HTR2C—GPCR downstream signaling—CALCA—thyroid cancer	9.29e-05	0.00113	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—TCF7L1—thyroid cancer	9.14e-05	0.00112	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—TCF7L1—thyroid cancer	9.1e-05	0.00111	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—TSHR—thyroid cancer	9.04e-05	0.0011	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—TSHR—thyroid cancer	9.03e-05	0.0011	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—TSHR—thyroid cancer	8.97e-05	0.0011	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—CDK1—thyroid cancer	8.97e-05	0.00109	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—PRKAR1A—thyroid cancer	8.89e-05	0.00109	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—PRKAR1A—thyroid cancer	8.88e-05	0.00108	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—PRKAR1A—thyroid cancer	8.83e-05	0.00108	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—SST—thyroid cancer	8.81e-05	0.00108	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—TSHR—thyroid cancer	8.78e-05	0.00107	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—SST—thyroid cancer	8.76e-05	0.00107	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—PRKAR1A—thyroid cancer	8.64e-05	0.00106	CbGpPWpGaD
Methysergide—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	8.58e-05	0.00105	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—MEN1—thyroid cancer	8.5e-05	0.00104	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—MEN1—thyroid cancer	8.49e-05	0.00104	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—CALCA—thyroid cancer	8.48e-05	0.00104	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—CALCA—thyroid cancer	8.44e-05	0.00103	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—MEN1—thyroid cancer	8.44e-05	0.00103	CbGpPWpGaD
Methysergide—HTR2A—GPCR downstream signaling—SST—thyroid cancer	8.38e-05	0.00102	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—PTCH1—thyroid cancer	8.32e-05	0.00102	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—MEN1—thyroid cancer	8.26e-05	0.00101	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—TSHR—thyroid cancer	8.25e-05	0.00101	CbGpPWpGaD
Methysergide—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	8.22e-05	0.001	CbGpPWpGaD
Methysergide—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	8.15e-05	0.000995	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—PRKAR1A—thyroid cancer	8.12e-05	0.000991	CbGpPWpGaD
Methysergide—HTR2A—GPCR downstream signaling—CALCA—thyroid cancer	8.07e-05	0.000985	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—TCF7L1—thyroid cancer	7.9e-05	0.000964	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—MEN1—thyroid cancer	7.76e-05	0.000947	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—PTCH1—thyroid cancer	7.69e-05	0.000938	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—PTCH1—thyroid cancer	7.68e-05	0.000937	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—CDK1—thyroid cancer	7.68e-05	0.000937	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—CDK1—thyroid cancer	7.64e-05	0.000932	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—NRG1—thyroid cancer	7.63e-05	0.000932	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—PTCH1—thyroid cancer	7.63e-05	0.000931	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—SST—thyroid cancer	7.61e-05	0.000929	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—PTCH1—thyroid cancer	7.47e-05	0.000912	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—CALCA—thyroid cancer	7.33e-05	0.000894	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—NRG1—thyroid cancer	7.2e-05	0.000879	CbGpPWpGaD
Methysergide—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	7.07e-05	0.000864	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—SST—thyroid cancer	7.03e-05	0.000858	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—SST—thyroid cancer	7.02e-05	0.000857	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—PTCH1—thyroid cancer	7.02e-05	0.000857	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—SST—thyroid cancer	6.98e-05	0.000852	CbGpPWpGaD
Methysergide—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	6.93e-05	0.000845	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—TERT—thyroid cancer	6.85e-05	0.000836	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—SST—thyroid cancer	6.83e-05	0.000834	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—CALCA—thyroid cancer	6.77e-05	0.000826	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—CALCA—thyroid cancer	6.76e-05	0.000825	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—CALCA—thyroid cancer	6.72e-05	0.00082	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—TSHR—thyroid cancer	6.69e-05	0.000817	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—TSHR—thyroid cancer	6.66e-05	0.000813	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—CDK1—thyroid cancer	6.63e-05	0.00081	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—PRKAR1A—thyroid cancer	6.58e-05	0.000804	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—CALCA—thyroid cancer	6.58e-05	0.000803	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—HIF1A—thyroid cancer	6.55e-05	0.0008	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—PRKAR1A—thyroid cancer	6.55e-05	0.0008	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—TERT—thyroid cancer	6.46e-05	0.000789	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—SST—thyroid cancer	6.42e-05	0.000783	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—MEN1—thyroid cancer	6.29e-05	0.000768	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—MEN1—thyroid cancer	6.26e-05	0.000764	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—HIF1A—thyroid cancer	6.18e-05	0.000755	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—CALCA—thyroid cancer	6.18e-05	0.000754	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—CDK1—thyroid cancer	6.13e-05	0.000748	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—CDK1—thyroid cancer	6.12e-05	0.000747	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—CDK1—thyroid cancer	6.08e-05	0.000742	CbGpPWpGaD
Methysergide—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	6.01e-05	0.000734	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—CDK1—thyroid cancer	5.95e-05	0.000727	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—TSHR—thyroid cancer	5.78e-05	0.000706	CbGpPWpGaD
Methysergide—HTR1F—Signaling by GPCR—NRAS—thyroid cancer	5.77e-05	0.000705	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—PTCH1—thyroid cancer	5.69e-05	0.000695	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PRKAR1A—thyroid cancer	5.69e-05	0.000694	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—PTCH1—thyroid cancer	5.66e-05	0.000691	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—CDK1—thyroid cancer	5.59e-05	0.000683	CbGpPWpGaD
Methysergide—HTR1E—Signaling by GPCR—NRAS—thyroid cancer	5.45e-05	0.000665	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—MEN1—thyroid cancer	5.44e-05	0.000664	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—BRAF—thyroid cancer	5.43e-05	0.000662	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—SST—thyroid cancer	5.2e-05	0.000635	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—SST—thyroid cancer	5.18e-05	0.000632	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—BRAF—thyroid cancer	5.12e-05	0.000625	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CALCA—thyroid cancer	5.01e-05	0.000612	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CALCA—thyroid cancer	4.98e-05	0.000608	CbGpPWpGaD
Methysergide—HTR1F—Signaling by GPCR—KRAS—thyroid cancer	4.97e-05	0.000607	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—NRG1—thyroid cancer	4.92e-05	0.0006	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PTCH1—thyroid cancer	4.92e-05	0.0006	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—NRG1—thyroid cancer	4.91e-05	0.0006	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—NRG1—thyroid cancer	4.88e-05	0.000596	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—NRG1—thyroid cancer	4.78e-05	0.000583	CbGpPWpGaD
Methysergide—HTR1E—Signaling by GPCR—KRAS—thyroid cancer	4.69e-05	0.000572	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CDK1—thyroid cancer	4.53e-05	0.000554	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CDK1—thyroid cancer	4.51e-05	0.000551	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—SST—thyroid cancer	4.5e-05	0.000549	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—NRG1—thyroid cancer	4.49e-05	0.000548	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—TERT—thyroid cancer	4.42e-05	0.000539	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—TERT—thyroid cancer	4.41e-05	0.000538	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—TERT—thyroid cancer	4.38e-05	0.000535	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CALCA—thyroid cancer	4.33e-05	0.000528	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—TERT—thyroid cancer	4.29e-05	0.000524	CbGpPWpGaD
Methysergide—HTR1F—Signaling by GPCR—HRAS—thyroid cancer	4.22e-05	0.000516	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—HIF1A—thyroid cancer	4.22e-05	0.000515	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—HIF1A—thyroid cancer	4.22e-05	0.000515	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—HIF1A—thyroid cancer	4.19e-05	0.000512	CbGpPWpGaD
Methysergide—HTR1F—GPCR downstream signaling—AKT1—thyroid cancer	4.11e-05	0.000501	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—HIF1A—thyroid cancer	4.1e-05	0.000501	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—TERT—thyroid cancer	4.03e-05	0.000492	CbGpPWpGaD
Methysergide—HTR1E—Signaling by GPCR—HRAS—thyroid cancer	3.98e-05	0.000486	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—CCND1—thyroid cancer	3.96e-05	0.000483	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CDK1—thyroid cancer	3.92e-05	0.000478	CbGpPWpGaD
Methysergide—HTR1E—GPCR downstream signaling—AKT1—thyroid cancer	3.87e-05	0.000473	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—HIF1A—thyroid cancer	3.85e-05	0.00047	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—PTEN—thyroid cancer	3.82e-05	0.000467	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—CCND1—thyroid cancer	3.74e-05	0.000456	CbGpPWpGaD
Methysergide—HTR1F—Signaling by GPCR—AKT1—thyroid cancer	3.73e-05	0.000455	CbGpPWpGaD
Methysergide—HTR6—Signaling by GPCR—NRAS—thyroid cancer	3.72e-05	0.000454	CbGpPWpGaD
Methysergide—HTR7—Signaling by GPCR—NRAS—thyroid cancer	3.72e-05	0.000454	CbGpPWpGaD
Methysergide—HTR1D—Signaling by GPCR—NRAS—thyroid cancer	3.69e-05	0.000451	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—NRG1—thyroid cancer	3.64e-05	0.000444	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—NRG1—thyroid cancer	3.62e-05	0.000442	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—NRAS—thyroid cancer	3.61e-05	0.000441	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—PTEN—thyroid cancer	3.61e-05	0.00044	CbGpPWpGaD
Methysergide—HTR1E—Signaling by GPCR—AKT1—thyroid cancer	3.52e-05	0.000429	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—BRAF—thyroid cancer	3.5e-05	0.000427	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—BRAF—thyroid cancer	3.49e-05	0.000426	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—BRAF—thyroid cancer	3.47e-05	0.000424	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—NRAS—thyroid cancer	3.41e-05	0.000416	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—BRAF—thyroid cancer	3.4e-05	0.000415	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—NRAS—thyroid cancer	3.4e-05	0.000414	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—TERT—thyroid cancer	3.27e-05	0.000399	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—TERT—thyroid cancer	3.25e-05	0.000397	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—NRAS—thyroid cancer	3.22e-05	0.000393	CbGpPWpGaD
Methysergide—HTR6—Signaling by GPCR—KRAS—thyroid cancer	3.2e-05	0.000391	CbGpPWpGaD
Methysergide—HTR7—Signaling by GPCR—KRAS—thyroid cancer	3.2e-05	0.00039	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—BRAF—thyroid cancer	3.19e-05	0.00039	CbGpPWpGaD
Methysergide—HTR1D—Signaling by GPCR—KRAS—thyroid cancer	3.18e-05	0.000388	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—NRG1—thyroid cancer	3.14e-05	0.000384	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—HIF1A—thyroid cancer	3.13e-05	0.000382	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—KRAS—thyroid cancer	3.11e-05	0.00038	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—HIF1A—thyroid cancer	3.11e-05	0.00038	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—KRAS—thyroid cancer	2.93e-05	0.000358	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—KRAS—thyroid cancer	2.92e-05	0.000357	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—TERT—thyroid cancer	2.82e-05	0.000345	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—KRAS—thyroid cancer	2.77e-05	0.000338	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—NRAS—thyroid cancer	2.75e-05	0.000336	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—NRAS—thyroid cancer	2.74e-05	0.000334	CbGpPWpGaD
Methysergide—HTR6—Signaling by GPCR—HRAS—thyroid cancer	2.72e-05	0.000332	CbGpPWpGaD
Methysergide—HTR7—Signaling by GPCR—HRAS—thyroid cancer	2.72e-05	0.000332	CbGpPWpGaD
Methysergide—HTR1D—Signaling by GPCR—HRAS—thyroid cancer	2.7e-05	0.00033	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—HIF1A—thyroid cancer	2.7e-05	0.00033	CbGpPWpGaD
Methysergide—HTR6—GPCR downstream signaling—AKT1—thyroid cancer	2.65e-05	0.000323	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—HRAS—thyroid cancer	2.64e-05	0.000323	CbGpPWpGaD
Methysergide—HTR7—GPCR downstream signaling—AKT1—thyroid cancer	2.64e-05	0.000323	CbGpPWpGaD
Methysergide—HTR1D—GPCR downstream signaling—AKT1—thyroid cancer	2.63e-05	0.000321	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—TP53—thyroid cancer	2.61e-05	0.000318	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—BRAF—thyroid cancer	2.59e-05	0.000316	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—BRAF—thyroid cancer	2.57e-05	0.000314	CbGpPWpGaD
Methysergide—HTR1B—GPCR downstream signaling—AKT1—thyroid cancer	2.57e-05	0.000314	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—CCND1—thyroid cancer	2.55e-05	0.000312	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—CCND1—thyroid cancer	2.55e-05	0.000311	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—CCND1—thyroid cancer	2.53e-05	0.000309	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—HRAS—thyroid cancer	2.49e-05	0.000305	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—HRAS—thyroid cancer	2.48e-05	0.000303	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—CCND1—thyroid cancer	2.48e-05	0.000303	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—PTEN—thyroid cancer	2.46e-05	0.000301	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—TP53—thyroid cancer	2.46e-05	0.0003	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—PTEN—thyroid cancer	2.46e-05	0.0003	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—PTEN—thyroid cancer	2.44e-05	0.000298	CbGpPWpGaD
Methysergide—HTR2B—GPCR downstream signaling—AKT1—thyroid cancer	2.42e-05	0.000295	CbGpPWpGaD
Methysergide—HTR6—Signaling by GPCR—AKT1—thyroid cancer	2.4e-05	0.000293	CbGpPWpGaD
Methysergide—HTR7—Signaling by GPCR—AKT1—thyroid cancer	2.4e-05	0.000293	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—PTEN—thyroid cancer	2.39e-05	0.000292	CbGpPWpGaD
Methysergide—HTR1D—Signaling by GPCR—AKT1—thyroid cancer	2.38e-05	0.000291	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—NRAS—thyroid cancer	2.38e-05	0.00029	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—KRAS—thyroid cancer	2.37e-05	0.000289	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—KRAS—thyroid cancer	2.36e-05	0.000288	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—HRAS—thyroid cancer	2.35e-05	0.000287	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—AKT1—thyroid cancer	2.33e-05	0.000285	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—CCND1—thyroid cancer	2.33e-05	0.000284	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—PTEN—thyroid cancer	2.25e-05	0.000274	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—BRAF—thyroid cancer	2.24e-05	0.000273	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—AKT1—thyroid cancer	2.2e-05	0.000269	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—NRAS—thyroid cancer	2.2e-05	0.000268	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—NRAS—thyroid cancer	2.19e-05	0.000268	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—AKT1—thyroid cancer	2.19e-05	0.000268	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—NRAS—thyroid cancer	2.18e-05	0.000266	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—NRAS—thyroid cancer	2.14e-05	0.000261	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—AKT1—thyroid cancer	2.08e-05	0.000254	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—KRAS—thyroid cancer	2.05e-05	0.00025	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—HRAS—thyroid cancer	2.01e-05	0.000246	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—NRAS—thyroid cancer	2.01e-05	0.000245	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—HRAS—thyroid cancer	2e-05	0.000245	CbGpPWpGaD
Methysergide—HTR1A—GPCR downstream signaling—AKT1—thyroid cancer	1.96e-05	0.000239	CbGpPWpGaD
Methysergide—HTR2C—GPCR downstream signaling—AKT1—thyroid cancer	1.95e-05	0.000238	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—KRAS—thyroid cancer	1.89e-05	0.000231	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—KRAS—thyroid cancer	1.89e-05	0.000231	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CCND1—thyroid cancer	1.89e-05	0.000231	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CCND1—thyroid cancer	1.88e-05	0.000229	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—KRAS—thyroid cancer	1.88e-05	0.000229	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—KRAS—thyroid cancer	1.84e-05	0.000224	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—PTEN—thyroid cancer	1.82e-05	0.000223	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—PTEN—thyroid cancer	1.81e-05	0.000221	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—AKT1—thyroid cancer	1.78e-05	0.000217	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—AKT1—thyroid cancer	1.77e-05	0.000216	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—HRAS—thyroid cancer	1.74e-05	0.000212	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—KRAS—thyroid cancer	1.73e-05	0.000211	CbGpPWpGaD
Methysergide—HTR2A—GPCR downstream signaling—AKT1—thyroid cancer	1.69e-05	0.000207	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—TP53—thyroid cancer	1.68e-05	0.000205	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—TP53—thyroid cancer	1.68e-05	0.000205	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—TP53—thyroid cancer	1.67e-05	0.000204	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—TP53—thyroid cancer	1.63e-05	0.000199	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CCND1—thyroid cancer	1.63e-05	0.000199	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—NRAS—thyroid cancer	1.63e-05	0.000199	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—NRAS—thyroid cancer	1.62e-05	0.000198	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—HRAS—thyroid cancer	1.61e-05	0.000196	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—HRAS—thyroid cancer	1.61e-05	0.000196	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—HRAS—thyroid cancer	1.6e-05	0.000195	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PTEN—thyroid cancer	1.58e-05	0.000192	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—HRAS—thyroid cancer	1.56e-05	0.000191	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—AKT1—thyroid cancer	1.54e-05	0.000188	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—TP53—thyroid cancer	1.53e-05	0.000187	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—HRAS—thyroid cancer	1.47e-05	0.000179	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—AKT1—thyroid cancer	1.42e-05	0.000173	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—AKT1—thyroid cancer	1.42e-05	0.000173	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—AKT1—thyroid cancer	1.41e-05	0.000172	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—NRAS—thyroid cancer	1.41e-05	0.000172	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—KRAS—thyroid cancer	1.4e-05	0.000171	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—KRAS—thyroid cancer	1.39e-05	0.00017	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—AKT1—thyroid cancer	1.38e-05	0.000168	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—AKT1—thyroid cancer	1.3e-05	0.000158	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—TP53—thyroid cancer	1.24e-05	0.000152	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—TP53—thyroid cancer	1.24e-05	0.000151	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—KRAS—thyroid cancer	1.21e-05	0.000148	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—HRAS—thyroid cancer	1.19e-05	0.000145	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—HRAS—thyroid cancer	1.18e-05	0.000145	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—TP53—thyroid cancer	1.07e-05	0.000131	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—AKT1—thyroid cancer	1.05e-05	0.000128	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—AKT1—thyroid cancer	1.05e-05	0.000128	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—HRAS—thyroid cancer	1.03e-05	0.000125	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—AKT1—thyroid cancer	9.08e-06	0.000111	CbGpPWpGaD
